spironolactone has been researched along with Abdominal Obesity in 3 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In EMPHASIS-HF, eplerenone improved outcomes in HFrEF patients with and without abdominal obesity, although the benefit appeared to be more pronounced among those with abdominal obesity." | 9.24 | Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS-HF trial. ( Collier, TJ; Girerd, N; Lamiral, Z; Machu, JL; McMurray, JJV; Olivier, A; Pitt, B; Pizard, A; Pocock, SJ; Rossignol, P; Swedberg, K; van Veldhuisen, DJ; Zannad, F, 2017) |
| "In EMPHASIS-HF, eplerenone improved outcomes in HFrEF patients with and without abdominal obesity, although the benefit appeared to be more pronounced among those with abdominal obesity." | 5.24 | Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS-HF trial. ( Collier, TJ; Girerd, N; Lamiral, Z; Machu, JL; McMurray, JJV; Olivier, A; Pitt, B; Pizard, A; Pocock, SJ; Rossignol, P; Swedberg, K; van Veldhuisen, DJ; Zannad, F, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahmed, A | 1 |
| Blackman, MR | 1 |
| White, M | 1 |
| Anker, SD | 1 |
| Medvedev, IN | 1 |
| Briukhovetskiĭ, AG | 1 |
| Olivier, A | 1 |
| Pitt, B | 1 |
| Girerd, N | 1 |
| Lamiral, Z | 1 |
| Machu, JL | 1 |
| McMurray, JJV | 1 |
| Swedberg, K | 1 |
| van Veldhuisen, DJ | 1 |
| Collier, TJ | 1 |
| Pocock, SJ | 1 |
| Rossignol, P | 1 |
| Zannad, F | 1 |
| Pizard, A | 1 |
2 trials available for spironolactone and Abdominal Obesity
| Article | Year |
|---|---|
[The use of verospiron and the degree of platelet aggregation in arterial hypertension with abdominal obesity].
Topics: Comorbidity; Diuretics; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Obesity, Abdom | 2014 |
Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS-HF trial.
Topics: Aged; Aldosterone; Drug Monitoring; Eplerenone; Female; Heart Failure, Systolic; Humans; Male; Middl | 2017 |
1 other study available for spironolactone and Abdominal Obesity
| Article | Year |
|---|---|
Emphasis on abdominal obesity as a modifier of eplerenone effect in heart failure: hypothesis-generating signals from EMPHASIS-HF.
Topics: Eplerenone; Heart Failure; Mineralocorticoid Receptor Antagonists; Obesity, Abdominal; Spironolacton | 2017 |